Integrative analysis of placental metabolic reprogramming and microbiome alterations in gestational diabetes mellitus (GDM).

Gestational diabetes mellitus (GDM) significantly impacts placental metabolism and microbial composition, leading to transformations at the maternal–fetal interface. In response to hyperglycemia, the placenta undergoes extensive metabolic reprogramming, including disturbances in lipid metabolism, reduced efficiency in fatty acid oxidation, altered amino acid transport, and adaptations in glycolysis. These metabolic changes are associated with inflammatory cytokine activity, mitochondrial stress, and endoplasmic reticulum dysfunction, collectively driving placental lipotoxicity and disruptions in nutrient transfer. Research underscores the critical role of regulatory pathways such as AMPK, PI3K/AKT, and PPARα–CPT1 in mediating these metabolic shifts, with specific metabolites, such as linoleic and α-linolenic acids, identified as promising biomarkers for GDM. The gut–placenta microbiome axis plays a key role in the development of GDM. Microbial imbalances, marked by a reduction in beneficial genera such as Bifidobacterium, Akkermansia, and Roseburia, coupled with an increase in pro-inflammatory species like Bacteroides and Desulfovibrio, influence both endocrine signaling and immune function. Notably, microbial metabolites like short-chain fatty acids have a complex impact by improving insulin sensitivity but potentially contributing to metabolic dysfunction when present in excessive amounts. Furthermore, research indicates that alterations in maternal microbiota can be transmitted vertically to the neonate, with long-term implications for metabolic health. Emerging omics-based research, integrating transcriptomics, proteomics, lipidomics, and metabolomics, provide a systems-level view of the molecular mechanisms driving GDM. These findings emphasize the intricate relationship between placental metabolic reprogramming and microbial dynamics in influencing maternal and fetal health outcomes and highlight novel opportunities for biomarker discovery and therapeutic intervention.